Currently, there are 25.03M common shares owned by the public and among those 16.54M shares have been available to trade.
The company’s stock has a 5-day price change of 75.24% and 18.52% over the past three months. SNSE shares are trading 12.72% year to date (YTD), with the 12-month market performance up to 13.89% higher. It has a 12-month low price of $0.38 and touched a high of $1.94 over the same period. SNSE has an average intraday trading volume of 58.45K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 54.62%, 42.82%, and -3.80% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Sensei Biotherapeutics Inc (NASDAQ: SNSE) shares accounts for 8.47% of the company’s 25.03M shares outstanding.
It has a market capitalization of $19.62M and a beta (3y monthly) value of 0.01. The earnings-per-share (ttm) stands at -$1.18. Price movements for the stock have been influenced by the stock’s volatility, which stands at 33.51% over the week and 14.95% over the month.
Earnings per share for the fiscal year are expected to increase by 8.24%, and -1.04% over the next financial year.
Looking at the support for the SNSE, a number of firms have released research notes about the stock. Stephens stated their Overweight rating for the stock in a research note on May 14, 2024, with the firm’s price target at $5. Berenberg coverage for the Sensei Biotherapeutics Inc (SNSE) stock in a research note released on July 01, 2021 offered a Hold rating with a price target of $12. Oppenheimer was of a view on June 29, 2021 that the stock is Perform, while Piper Sandler gave the stock Overweight rating on March 01, 2021, issuing a price target of $25. Oppenheimer on their part issued Outperform rating on March 01, 2021.
